The stock price for Bristol-Myers Squibb Co (BMY) currently stands at $44.23. The stock experienced a substantial increase in the last session, hitting $68.0 after starting at $44.23. The stock’s lowest price was $34.0 before closing at $43.31.
Bristol-Myers Squibb Co’s market performance has been unstable in recent times.
52-week price history of BMY Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Bristol-Myers Squibb Co’s current trading price is -30.16% away from its 52-week high, while its distance from the 52-week low is 2.96%. The stock’s price range during the 52-week period has remained between $42.96 and $63.33. In the Healthcare sector, the company’s shares saw a trading volume of around 18.62 million for the day, which was evidently higher than the average daily volume of 14.4 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Bristol-Myers Squibb Co (BMY) has experienced a quarterly decline of -10.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 90.03B and boasts a workforce of 34100 employees.
A Closer Look at Analysts’ Ratings for Bristol-Myers Squibb Co
As of right now, 4 analysts are rating Bristol-Myers Squibb Co as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 18 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 50.29, with a change in price of -18.88. Similarly, Bristol-Myers Squibb Co recorded 14,426,320 in trading volume during the last 100 days, posting a change of -29.92%.
Examining BMY’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for BMY stands at 2.92. Similarly, the long-term debt-to-equity ratio is also 2.64.
BMY Stock Stochastic Average
As of today, Bristol-Myers Squibb Co’s raw stochastic average for the last 50 days stands at 16.28%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 20.11%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 10.19% and 14.85%, respectively.
BMY Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. This year’s metric has recorded a Price decrease of -9.83%. However, over the past six months, we’ve seen a stronger performance of -25.21%. The price of BMY leaped by -7.14% over the last 30 days. And in the last five days, it has fallen by -8.67%.
